Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) reported to the Hong Kong Stock Exchange that it bought back 20,000 H shares on 10 April 2026. The repurchase represents 0.015% of the company’s outstanding shares (excluding treasury stock).

The shares were acquired on-market at a volume-weighted average price of HK$30.1278, within a trading range of HK$29.50–30.435238. Cash consideration for the transaction totaled HK$602,556. All 20,000 shares have been retained as treasury stock; no cancellations were recorded.

Following the buyback, issued shares outstanding (excluding treasury stock) declined from 136.13 million to 136.11 million. Treasury shares increased from 86,100 to 106,100, while total issued shares remained unchanged at 136.22 million.

The transaction forms part of the repurchase mandate approved on 12 February 2026, which authorizes HANXBIO-B to buy back up to 13.62 million shares. Cumulative repurchases under this mandate now stand at 106,100 shares, equating to 0.0779% of the share count on the mandate date. In accordance with Hong Kong Listing Rules, the company is subject to a moratorium on new share issues or treasury-share sales until 10 May 2026.